IL1R1 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, the combination of a recombinant IL-1R antagonist (IL-1RA) with a TKI resulted in significantly greater inhibition of CML LSCs compared with the TKI alone33.